TB-500

A synthetic analogue of the active region of Thymosin Beta-4, found at high concentrations in virtually every human and animal cell. Distinguished from BPC-157 by systemic action, travelling through the bloodstream mobilising repair cells across the body.

Binds G-actin monomers regulating cytoskeletal dynamics, promotes directed cell migration to injury sites, stimulates new blood vessel formation, reduces pro-inflammatory cytokines IL-4 and IL-10, and activates progenitor cell differentiation.

Where BPC-157 is a local repair crew sent to the damage site, TB-500 is a system-wide distress signal that mobilises repair cells from across the body. Research investigates whether it helps with healing that is slow, widespread or resistant to localised treatment. Racehorses were the first to benefit.

• Actin binding and cytoskeletal dynamics
• Cell migration rate to injury sites
• Angiogenesis and capillary density
• IL-4 and IL-10 cytokine levels
• Wound closure rate
• Cardiac function post-ischaemia

• Wound healing and skin repair
• Cardiac muscle repair post-ischaemia
• Systemic inflammatory response modulation
• Hair follicle stem cell activation
• Equine soft tissue injury recovery
• Corneal tissue migration
• Neural tissue migration and regeneration

Thymosin Beta-4 was first identified in bovine thymus in the 1960s by Dr Allan Goldstein. It gained attention through equine sports medicine in the 2000s and was prohibited by WADA in 2011.

Men and women 25-60, athletes, systemic or widespread healing needs, and injury recovery.

• Reconstitute with bacteriostatic water into the vial wall.
• Swirl gently until fully dissolved.
• Store lyophilised at -20C away from moisture.
• Reconstituted solution stable 30 days at 4C.
• Avoid freeze-thaw cycles.

• Longer half-life than BPC-157, less frequent dosing in protocols.
• Systemic action, a different mechanism to BPC-157's local effect.
• WADA prohibited, relevant for sports research contexts.
• Frequently studied alongside BPC-157 in combined repair models.